| Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial). | |
| | |
MedLine Citation:
|
PMID: 19101227 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Low high-density lipoprotein (HDL) cholesterol is a strong independent predictor of cardiovascular risk. The present study was designed to assess the relation between the clinical response to HDL cholesterol modification and serum levels of low-density lipoprotein (LDL) cholesterol in patients with coronary artery disease (CAD). The risk for a major cardiac event (defined as nonfatal myocardial infarction or cardiac death) during a median 7.9-year follow-up period in 3,020 patients with CAD enrolled in the Bezafibrate Infarction Prevention (BIP) trial was related to changes in lipid levels during the study. Baseline LDL cholesterol levels were categorized according to National Cholesterol Education Program Adult Treatment Panel III criteria. Multivariate analysis demonstrated that the benefit of HDL cholesterol increase was most pronounced in patients with low baseline LDL cholesterol (<or=129 mg/dl; 29% risk reduction per 5 mg/dl increment in HDL cholesterol, p = 0.02), intermediate in patients with intermediate LDL cholesterol (130 to 159 mg/dl; 13% risk reduction per 5 mg/dl increment in HDL cholesterol, p = 0.03), and nonsignificant in patients with high LDL cholesterol (>or=160 mg/dl; hazard ratio 0.94, 95% confidence interval 0.75 to 1.17, p = 0.14). A similar relation was shown for risk reduction-associated triglyceride decrements, whereas the benefit of LDL cholesterol reduction was more pronounced in patients with baseline LDL cholesterol >or=130 mg/dl. In conclusion, these data suggest that the clinical response to HDL cholesterol and triglyceride modification is inversely related to baseline LDL cholesterol levels. Thus, combined assessment of baseline and follow-up lipid levels to direct therapeutic goals in patients with CAD may provide incremental prognostic information to secondary prevention that is based solely on LDL cholesterol modification. |
| | |
Authors:
|
Ilan Goldenberg; Michal Benderly; Roy Sidi; Valentina Boyko; Alexander Tenenbaum; David Tanne; Shlomo Behar |
Related Documents
:
|
3632757 - Long-term effects of a linoleic acid-enriched diet, changes in body weight and alcohol ... 19405827 - The relationship between serum lipids and periodontitis in elderly non-smokers. 21073127 - Glycogen storage disease type iii with hypoketosis. 748427 - Serum cholesterol and triglycerides and hyperlipoproteinemia in elderly women. 21642497 - Effect of herbage depletion on short-term foraging dynamics and diet quality of steers ... 21943297 - Drinking carrot juice increases total antioxidant status and decreases lipid peroxidati... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial Date: 2008-10-10 |
Journal Detail:
|
Title: The American journal of cardiology Volume: 103 ISSN: 1879-1913 ISO Abbreviation: Am. J. Cardiol. Publication Date: 2009 Jan |
Date Detail:
|
Created Date: 2008-12-22 Completed Date: 2009-01-13 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0207277 Medline TA: Am J Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 41-5 Citation Subset: AIM; IM |
Affiliation:
|
Heart Institute, Sheba Medical Center, Tel Hashomer, Israel. ilan.goldenberg@heart.rochester.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Antilipemic Agents / therapeutic use* Bezafibrate / therapeutic use* Biological Markers / blood Cholesterol, HDL / blood* Cholesterol, LDL / blood* Coronary Disease / blood*, complications, mortality Female Follow-Up Studies Humans Israel / epidemiology Male Middle Aged Myocardial Infarction / blood, etiology, prevention & control* Prognosis Prospective Studies Survival Rate / trends Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/Antilipemic Agents; 0/Biological Markers; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 41859-67-0/Bezafibrate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effectiveness of atrial fibrillation as an independent predictor of death and coronary events in pat...
Next Document: Relation of serum fetuin-A levels to coronary artery calcium in African-American patients on chronic...